Balanced news tone
News Sentiment
GILD sentiment intelligence
Gilead Sciences, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
86/100 classification confidence.
directly relevant articles
high-authority source matches
+5.5% over one week, +13.4% over four weeks, trend inactive, and materially above fair value.
Gilead Sciences Inc (GILD) Stock Up 3.5% but GF Value Says Overv
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Gilead Sciences Inc (GILD) Stock Up 3.5% but GF Value Says Overv
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 21:35
- Source
- GuruFocus
Gilead Sciences (NASDAQ: GILD) exec trades 3,000 shares under 10b5-1 plan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 20:55
- Source
- Stock Titan
Planned 3,000-share sale by Gilead (NASDAQ: GILD) shareholder Johanna Mercier
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 20:13
- Source
- Stock Titan
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 10 Jul 2026 07:00
- Source
- Market source
Gilead (GILD) Stock Looks Below Fair Value But Earnings Already Look Priced In
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 09 Jul 2026 07:00
- Source
- simplywall.st
Should First-Line Trodelvy Breast Cancer Approvals Reshape the Gilead Sciences (GILD) Investment Narrative?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 07:00
- Source
- simplywall.st
Gilead Sciences Stock (GILD) Opinions on Recent Congressional Insider Activity
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- Quiver Quantitative
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- Market source
Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Weakness
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 07:00
- Source
- Market source
Gilead's drug wins first-ever US approval for deadly liver infection
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 26 May 2026 07:00
- Source
- Reuters
Is It Time To Reassess Gilead Sciences (GILD) After Strong Multi Year Share Price Gains
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 23 May 2026 07:00
- Source
- Market source
Gilead Sciences Just Told Investors What to Watch Before December 23. Here’s What the Data Says About GILD Stock.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 May 2026 07:00
- Source
- TIKR.com
California's highest court leans toward Gilead in considering drugmakers' 'duty to innovate'
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 May 2026 07:00
- Source
- Reuters
Gilead Sciences Inc. (GILD): Growing Popularity as Defensive Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Apr 2026 07:00
- Source
- Market source
Gilead Sciences Deploys $16 Billion in 60 Days: Is GILD Stock Undervalued for 2026?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Apr 2026 07:00
- Source
- TIKR.com
Gilead to Buy Cancer Biotech Tubulis in $5 Billion Deal
- Tone
- Positive 66/100
- Event
- Deals and strategy
- Published
- 07 Apr 2026 07:00
- Source
- Bloomberg.com
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Mar 2026 07:00
- Source
- Market source
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 05 Jan 2026 08:00
- Source
- Market source
Gilead posts higher profit on demand for HIV drugs, but overall sales dip
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 30 Oct 2025 07:00
- Source
- Reuters
Does Gilead's drug lenacapavir have the power to end the AIDS epidemic? - San Francisco Business Times
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 May 2025 07:00
- Source
- The Business Journals
GILEAD SCIENCES APPOINTS PAUL PETRELLI TO VICE PRESIDENT AND GENERAL MANAGER IN CANADA
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Nov 2024 08:00
- Source
- PR Newswire Canada
Gilead Sciences raises stake in cancer-centric Arcus Biosciences to 33%
- Tone
- Positive 66/100
- Event
- Deals and strategy
- Published
- 29 Jan 2024 08:00
- Source
- Reuters
Gilead and HRC launch $5M initiative to end HIV epidemic by 2030
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 31 May 2023 07:00
- Source
- HRC | Human Rights Campaign
Gilead is buying Kite Pharma, a cancer-fighting Santa Monica biotech firm, for $11.9 billion
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Aug 2017 07:00
- Source
- Los Angeles Times
Gilead shares plunge after Express Scripts spurns its $1,000 hepatitis C pill
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Dec 2014 08:00
- Source
- Los Angeles Times